Rivastigmine Market Size, Trends, Shares, Insights and Forecast – 2018-2026

Rivastigmine Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
 
SEATTLE - July 22, 2021 - PRLog -- Rivastigmine Market, by Disease Indication (Alzheimer Disease and Parkinson's Disease), by Formulation ( Capsules and Transdermal Patches), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Geography (North America, Asia Pacific, Europe, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018- 2026

Rivastigmine is a cholinesterase enzyme inhibitor, which acts on butylcholinesterase and acetylcholinesterase. It is a cholinergic agent that aids in the treatment of Alzheimer's and Parkinson's disease. The drug can be administered orally or in transdermal patches form, owing to its small molecular size.

Rivastigmine Market – Dynamics

Increasing geriatric population is a major driver for growth of the rivastigmine market. According to The Alzheimer Association, in 2018, the risk of suffering from dementia can increase double fold above the age of 65 years in every 5 years. Moreover, increasing prevalence of cardiovascular diseases worldwide also accounts for the development of Alzheimer's disease, thereby boosting demand for rivastigmine.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2407

Diseases such as diabetes and blood pressure can also increase the risk of dementia, which further boosts demand for rivastigmine, thereby propelling the market growth.

Rivastigmine Market – Regional Insights

The rivastigmine market is segregated geographically into North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. North America accounted for the largest share in the global rivastigmine market in 2017. This is owing to increasing prevalence of chronic kidney disease in the region that may lead to dementia. According to The American Kidney Fund, around 31 million people suffered from chronic kidney disease in 2015. Europe accounted for the second largest share in terms of revenue in the global rivastigmine market, in 2017 owing to increasing geriatric population in the region.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/rivastigmine-market-2407

Rivastigmine Market – Competitive Landscape

Major players operating in the global rivastigmine market include, Novartis Europharm Limited, Actavis Pharma, Apotex Corporation, Aurobindo Pharm Ltd, Teva Pharmaceuticals Industries Ltd, Dr. Reddy's Laboratories, Macleods, and others. Key players in the market are focused on product development and approvals in order to enhance their market share. For instance, in 2007, U.S. FDA approved Exelon (Rivastigmine tartarate) — developed by Novartis Europharm Limited for the treatment of Alzheimer's and Parkinson's disease.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2407

Contact
Mr. Shah
sales@coherentmarketinsights.com
+1-206-701-6702
End
Source: » Follow
Email:***@coherentmarketinsights.com
Posted By:***@coherentmarketinsights.com Email Verified
Tags:Healthcare
Industry:Health
Location:Seattle - Washington - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Coherent Market Insights PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share